Aerie Pharmaceuticals Inc. may have to overcome safety concerns in trying to gain approval for the first in a new class of drugs to treatment of elevated intraocular pressure.
The company has proposed once-daily netarsudil, proposed trade name Rhopressa, for reduction of elevated intraocular pressure (IOP) in patients with...





